# Vivanza Bio (NSE: VIVANZA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VIVANZA · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹7 Cr, it ranks 4001st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 9.0% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹6 Cr (+1,225.0% year on year) and net profit −₹0 Cr, on a consolidated basis. Promoters held 20.02% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹7 Cr |
| ROE | 9.0% (FY26) |
| ROCE | 15.7% (FY26) |
| Debt to equity | 2.34 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹6 Cr | +1,225.0% | −₹0 Cr | — | −₹0.11 |
| Q3 FY26 | ₹45 Cr | +2,916.7% | ₹0 Cr | +400.0% | ₹0.05 |
| Q2 FY26 | ₹55 Cr | +1,745.3% | ₹1 Cr | +2,700.0% | ₹0.14 |
| Q1 FY26 | ₹9 Cr | +266.4% | ₹0 Cr | −66.7% | ₹0.02 |
| Q4 FY25 | ₹0 Cr | −89.1% | −₹1 Cr | — | −₹0.25 |
| Q3 FY25 | ₹2 Cr | −77.1% | ₹0 Cr | −81.0% | ₹0.01 |
| Q2 FY25 | ₹3 Cr | −60.6% | ₹0 Cr | −92.3% | ₹0.00 |
| Q1 FY25 | ₹2 Cr | −73.6% | ₹0 Cr | −44.9% | ₹0.07 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7 Cr | −₹1 Cr |
| FY24 | ₹28 Cr | ₹1 Cr |
| FY23 | ₹18 Cr | ₹1 Cr |
| FY22 | ₹10 Cr | ₹0 Cr |
| FY21 | ₹10 Cr | ₹0 Cr |
| FY20 | ₹10 Cr | −₹0 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 20.02%
- Domestic institutions: 0.00%
- Non-institutions: 79.98%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Trinity League](https://app.pivotnow.in/stock/TRINITYLEA) | — | ₹8 Cr | — | — |
| [Adline Chem Lab](https://app.pivotnow.in/stock/ADLINE) | — | ₹8 Cr | — | — |
| [Unjha Formula](https://app.pivotnow.in/stock/UNJHAFOR) | — | ₹8 Cr | — | — |
| [Dr Lalchandani](https://app.pivotnow.in/stock/DLCL) | — | ₹7 Cr | — | — |
| [DECIPHER LABS](https://app.pivotnow.in/stock/DECIPHER) | — | ₹6 Cr | — | — |
| [Evoq Remedies](https://app.pivotnow.in/stock/EVOQ) | — | ₹6 Cr | — | — |

## Questions and answers

### What is the market cap of Vivanza Bio?

Vivanza Bio's market capitalisation is ₹7 Cr (₹7 Cr) at the 22 Oct 2026 close, ranking 4001st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Vivanza Bio?

Return on equity was 9.0% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures).

### Is Vivanza Bio a debt-free company?

No. Vivanza Bio's debt-to-equity ratio was 2.34 in FY26, with total debt of ₹1 Cr.

### What were Vivanza Bio's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Vivanza Bio reported revenue of ₹6 Cr, +1,225.0% year on year, and net profit of −₹0 Cr.

### What is the shareholding pattern of Vivanza Bio?

As of 31 Mar 2026: promoters 20.02%, domestic institutions 0.00%, non-institutions 79.98%.

### Who are Vivanza Bio's competitors?

The listed Pharma & Healthcare companies closest to Vivanza Bio by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Dr Lalchandani, DECIPHER LABS and Evoq Remedies.

### Is Vivanza Bio a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vivanza Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIVANZA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.